Merus (MRUS) News Today → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free MRUS Stock Alerts $54.87 -5.12 (-8.53%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 2:56 AM | americanbankingnews.comMerus (NASDAQ:MRUS) Price Target Raised to $93.00May 29 at 1:28 AM | americanbankingnews.comMerus (NASDAQ:MRUS) Sees Large Volume Increase After Analyst UpgradeMay 28 at 4:01 PM | globenewswire.comMerus N.V. Announces Proposed Public Offering of Common SharesMay 28 at 12:21 PM | marketbeat.comMerus (NASDAQ:MRUS) Sees Large Volume Increase on Analyst UpgradeMerus (NASDAQ:MRUS) Sees Large Volume Increase After Analyst UpgradeMay 28 at 12:15 PM | marketbeat.comGuggenheim Raises Merus (NASDAQ:MRUS) Price Target to $93.00Guggenheim upped their price target on Merus from $57.00 to $93.00 and gave the stock a "buy" rating in a research note on Tuesday.May 28 at 7:43 AM | finance.yahoo.comMerus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCCMay 28 at 7:00 AM | globenewswire.comMerus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCCMay 26 at 5:52 AM | americanbankingnews.comMerus (NASDAQ:MRUS) Price Target Raised to $61.00May 26 at 5:06 AM | americanbankingnews.comMerus (NASDAQ:MRUS) Stock Rating Reaffirmed by HC WainwrightMay 26 at 4:39 AM | marketbeat.comBNP Paribas Financial Markets Purchases 36,160 Shares of Merus (NASDAQ:MRUS)BNP Paribas Financial Markets grew its position in Merus (NASDAQ:MRUS - Free Report) by 135.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,825 shares of the biotechnology company's stock after acqMay 26 at 3:58 AM | americanbankingnews.comMerus (NASDAQ:MRUS) Rating Reiterated by Needham & Company LLCMay 25, 2024 | marketbeat.comSwiss National Bank Has $2 Million Holdings in Merus (NASDAQ:MRUS)Swiss National Bank decreased its stake in Merus (NASDAQ:MRUS - Free Report) by 22.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 72,654 shares of the biotechnology company's stock after selling 20,700 shares durinMay 25, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Hits New 12-Month High After Analyst UpgradeMay 25, 2024 | americanbankingnews.comInvestors Purchase High Volume of Merus Put Options (NASDAQ:MRUS)May 24, 2024 | barrons.comMerus Clears Wall Street's Bar With Cancer DataMay 24, 2024 | seekingalpha.comMerus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)May 24, 2024 | finance.yahoo.comWhy Is Cancer-Focused Merus Stock Trading Over 30% On Friday?May 24, 2024 | msn.comMerus rallies on publication of oncology study abstractsMay 24, 2024 | markets.businessinsider.comMerus’s Petosemtamab Shows Promising Trial Results, Analyst Recommends Buy with $54 Price TargetMay 24, 2024 | marketbeat.comTraders Purchase High Volume of Put Options on Merus (NASDAQ:MRUS)Merus (NASDAQ:MRUS - Get Free Report) was the recipient of some unusual options trading activity on Friday. Stock traders acquired 4,020 put options on the company. This is an increase of 739% compared to the average daily volume of 479 put options.May 24, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Hits New 52-Week High After Analyst UpgradeMerus (NASDAQ:MRUS) Reaches New 52-Week High After Analyst UpgradeMay 24, 2024 | investors.comWhy Top 4% Biotech Stock, Merus, Just Catapulted To A Record HighMay 24, 2024 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for Merus (NASDAQ:MRUS)Needham & Company LLC reaffirmed a "buy" rating and issued a $66.00 price objective on shares of Merus in a research report on Friday.May 23, 2024 | finanznachrichten.deMerus N.V.: Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual MeetingMay 23, 2024 | globenewswire.comMerus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual MeetingMay 23, 2024 | globenewswire.comMerus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual MeetingMay 22, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Rating Lowered to Sell at StockNews.comMay 22, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Downgraded by StockNews.comMay 22, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Downgraded by StockNews.com to "Sell"StockNews.com downgraded Merus from a "hold" rating to a "sell" rating in a research report on Wednesday.May 17, 2024 | marketbeat.com46,120 Shares in Merus (NASDAQ:MRUS) Acquired by Jump Financial LLCJump Financial LLC acquired a new stake in Merus (NASDAQ:MRUS - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 46,120 shares of the biotechnology company's stock, valued at approximately $1,268,000. Jump Financial LLC owned aboutMay 17, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Receives Average Recommendation of "Buy" from AnalystsShares of Merus (NASDAQ:MRUS - Get Free Report) have earned a consensus recommendation of "Buy" from the eleven analysts that are covering the firm, Marketbeat.com reports. Eleven research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts thaMay 15, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Upgraded to "Hold" by StockNews.comStockNews.com raised Merus from a "sell" rating to a "hold" rating in a research report on Tuesday.May 13, 2024 | finanznachrichten.deMerus N.V.: Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDAMay 13, 2024 | markets.businessinsider.comMerus Says FDA Grants Breakthrough Therapy Designation For Petosemtamab To Treat Head & Neck CancerMay 13, 2024 | markets.businessinsider.comBuy Rating on Merus Stock Amid Anticipation of Positive Clinical Trial Results and Growing Investor InterestMay 13, 2024 | msn.comMerus gets FDA breakthrough therapy status for petosemtamabMay 13, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $66.00 price objective on shares of Merus in a research note on Monday.May 13, 2024 | globenewswire.comPetosemtamab granted Breakthrough Therapy Designation by the U.S. FDAMay 11, 2024 | finance.yahoo.comMerus N.V. (NASDAQ:MRUS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 10, 2024 | finance.yahoo.comInvestors push Merus (NASDAQ:MRUS) 5.0% lower this week, company's increasing losses might be to blameMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on Merus’s Clinical and Financial ProspectsMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Merus on Promising HNSCC Clinical Data and Competitive OutlookMay 9, 2024 | investorplace.comMRUS Stock Earnings: Merus Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | finanznachrichten.deMerus N.V.: Merus Announces Financial Results for the First Quarter 2024 and Provides Business UpdateMay 8, 2024 | globenewswire.comMerus Announces Financial Results for the First Quarter 2024 and Provides Business UpdateMay 6, 2024 | msn.comFDA accepts Merus application for Zeno for lung, pancreatic cancerMay 6, 2024 | globenewswire.comMerus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDACApril 26, 2024 | seekingalpha.comMRUS Merus N.V.April 25, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Shares Up 5.1%Merus (NASDAQ:MRUS) Trading Up 5.1%April 25, 2024 | finance.yahoo.comWill Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Banking Apocalypse Ahead: Secure Your Savings Today! (Ad)During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. We warned about 484 — an accuracy rate of 99.8% Now, I have a new warning. See what it is here! MRUS Media Mentions By Week MRUS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRUS News Sentiment▼0.340.82▲Average Medical News Sentiment MRUS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRUS Articles This Week▼353▲MRUS Articles Average Week Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TG Therapeutics News Today ACADIA Pharmaceuticals News Today MoonLake Immunotherapeutics News Today Janux Therapeutics News Today Bausch Health Companies News Today Maravai LifeSciences News Today Arvinas News Today Indivior News Today MorphoSys News Today Rhythm Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRUS) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersYou won't believe what Citigroup just did to it's depositorsAmerican Alternative4 Cryptos BETTER than BitcoinTrue Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaWrite this ticker symbol down…StocksToTradeBill Clinton Backing Biden Replacement???The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
